The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Amyloid Abeta In The Natural History Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$220,475.00
Summary
This grant is the continuation of a large series of experiments designed to uncover the basic causes of Alzheimer's disease. The focus is on closing some of the gaps in our knowledge of the natural history of Alzheimer's disease in relation to the deposition of the Abeta amyloid protein in the brain, which we believe plays a central role in the degeneration of nerve cells in this condition. The main questions we are tackling include: the feasibility of using assays of Abeta in the blood as a bio ....This grant is the continuation of a large series of experiments designed to uncover the basic causes of Alzheimer's disease. The focus is on closing some of the gaps in our knowledge of the natural history of Alzheimer's disease in relation to the deposition of the Abeta amyloid protein in the brain, which we believe plays a central role in the degeneration of nerve cells in this condition. The main questions we are tackling include: the feasibility of using assays of Abeta in the blood as a biological marker of Alzheimer's disease; whether better transgenic mouse models of Alzheimer's disease are required; whether the soluble forms of Abeta amyloid are the major species which cause neurotoxicity (in contrast to the insoluble forms which constitute the bulk of this protein in the Alzheimer's disease brain); and whether the intracellular or extracellular pathways of Abeta aggregation and toxicity are the key to understanding this disease. Increasing evidence suggests that the clearance of soluble forms of the Abeta protein from the brain may be a major therapeutic strategy. We therefore require further investigations of how these soluble forms of Abeta are generated in nerve cells, and how these forms exist in equilibrium with soluble and insoluble pools in the brain, cerebrospinal fluid, blood and other tissues of the body.Read moreRead less
Characterization Ol A Novel Covalently Cross -linked Abeta Peptide Dimer And Its Role In Alzheimers Disease.
Funder
National Health and Medical Research Council
Funding Amount
$553,236.00
Summary
Currently there are limited therapeutic treatments and no cure for Alzheimer's disease (AD). The key protein causing AD is called Abeta. Abeta peptides form dityrosine cross-linked dimers (when 2 peptides join together) and this is thought to be responsible for killing brain cells in AD. Therefore, this proposal will determine the role of Abeta dimers in relation to killing brain cells and the progression of AD through analysis of their biological and biochemical properties.
Functional Studies On A Neuroprotective Activity Of The Amyloid Precursor Protein Of Alzheimer S Disease.
Funder
National Health and Medical Research Council
Funding Amount
$160,475.00
Summary
Alzheimer's disease is a major health problem of the elderly. With our aging population living longer, this presents enormous economic and social pressures. Research into the mechanism of Alzheimer's disease is therefore of immediate importance. In this study we are trying to determine the relationship between proteins involved in the disease process. In particular we are studying the amyloid precursor protein (APP). APP has both therapeutic as well as disease causing actions. It gives rise to t ....Alzheimer's disease is a major health problem of the elderly. With our aging population living longer, this presents enormous economic and social pressures. Research into the mechanism of Alzheimer's disease is therefore of immediate importance. In this study we are trying to determine the relationship between proteins involved in the disease process. In particular we are studying the amyloid precursor protein (APP). APP has both therapeutic as well as disease causing actions. It gives rise to the toxic amyloid peptide Abeta which is responsible for disease. However APP can also inhibit Abeta toxicity thus controlling cell death. We are studying how APP is able to modulate the neurotoxic activity of Abeta. These studies will identify key aspects of the disease pathway and hopefully lead to treatment strategies.Read moreRead less
Delineating The Interaction Between The Amyloid Precursor Protein Family And SorLA-LR11
Funder
National Health and Medical Research Council
Funding Amount
$749,022.00
Summary
The Alzheimer's disease Amyloid Precursor Protein (APP) is central to the cause of Alzheimer's disease (AD). It's metabolised into the neurotoxic amyloid beta (Abeta) peptide that is deposited in AD brains. The sorLA protein is a neuronal protein that interacts with APP and alters its metabolism into Abeta. This grant will study the interaction between APP and sorLA and define the APP binding site for sorLA which represents a potential drug target.
Modulation Of Neurotherapeutic Cell Signalling Pathways By Metallo-complexes As A Treatment For Alzheimers Disease.
Funder
National Health and Medical Research Council
Funding Amount
$653,113.00
Summary
Alzheimer's disease (AD) is an enormous burden on the Australian health care system . We have begun to investigate therapeutic treatments based on triggering protective cell signalling pathways with metal-based compounds. These compounds trigger the activation of a signalling cascade resulting in inhibition of AD-associated symptoms. In this proposal we will further investigate how these compounds modulate specific receptors and cellular kinase activity to protect neurons in the AD brain.